Results of a randomized trial comparing MVPP chemotherapy with a hybrid regimen, ChlVPP/EVA, in the initial treatment of Hodgkin's disease.
Authors
Radford, John ACrowther, Derek
Rohatiner, Ama
Ryder, W David J
Gupta, R K
Oza, A
Deakin, David P
Arnott, S
Wilkinson, Peter M
James, Roger D
Affiliation
Cancer Research Campaign Department of Medical Oncology, Christie Hospital National Health Service Trust. Manchester, United Kingdom.Issue Date
1995-09
Metadata
Show full item recordAbstract
PURPOSE AND METHODS: Between December 1984 and August 1992, 423 patients with newly diagnosed Hodgkin's disease (HD) were entered onto a randomized clinical trial that compared the regimen of mechlorethamine, vinblastine, procarbazine, and prednisone (MVPP) with a doxorubicin-containing hybrid regimen (chlorambucil, vinblastine, procarbazine, and prednisone/etoposide, vincristine, and doxorubicin [ChlVPP/EVA]). Median age for the group was 29.5 years (range, 15.2 to 68.8), and 52% had bulk disease. RESULTS: After chemotherapy, patients in the hybrid arm of the trial had a higher complete remission (CR) rate (68.1% v 55.3%) and a lower failure rate (2.4% v 12.5%) than those in the MVPP arm. There were also fewer deaths during treatment in the hybrid arm of the trial (five v 13). With a median follow-up period for survivors of 4.5 years (range, 0 to 9), actuarial 5-year progression-free survival (PFS) for all cases is 80% in the hybrid arm and 66% in the MVPP arm (P = .005). A nonsignificant trend toward a better overall survival in the hybrid arm of the trial has also been identified. CONCLUSION: These results suggest that ChlVPP/EVA hybrid is superior to MVPP in the treatment of HD. It has therefore been adopted as standard first-line therapy at the two centers.Citation
Results of a randomized trial comparing MVPP chemotherapy with a hybrid regimen, ChlVPP/EVA, in the initial treatment of Hodgkin's disease. 1995, 13 (9):2379-85 J. Clin. Oncol.Journal
Journal of Clinical OncologyPubMed ID
7666097Type
ArticleLanguage
enISSN
0732-183XCollections
Related articles
- ChlVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin's disease.
- Authors: Radford JA, Rohatiner AZ, Ryder WD, Deakin DP, Barbui T, Lucie NP, Rossi A, Dunlop DJ, Cowan RA, Wilkinson PM, Gupta RK, James RD, Shamash J, Chang J, Crowther D, Lister TA
- Issue date: 2002 Jul 1
- ChlVPP alternating with PABlOE is superior to PABlOE alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation/Central Lymphoma Group randomized controlled trial.
- Authors: Hancock BW, Gregory WM, Cullen MH, Hudson GV, Burton A, Selby P, Maclennan KA, Jack A, Bessell EM, Smith P, Linch DC, British National Lymphoma Investigation, Central Lymphoma Group
- Issue date: 2001 May 18
- ChlVPP/PABlOE and radiotherapy in advanced Hodgkin's disease. The Central Lymphoma Group.
- Authors: Cullen MH, Stuart NS, Woodroffe C, Murphy A, Fletcher J, Blackledge GR, Child JA, Grieve RJ, Jones EL
- Issue date: 1994 Apr
- Can MOPP be replaced in the treatment of advanced Hodgkin's disease?
- Authors: Canellos GP
- Issue date: 1990 Feb
- Etoposide, vinblastine, and doxorubicin: an active regimen for the treatment of Hodgkin's disease in relapse following MOPP. Cancer and Leukemia Group B.
- Authors: Canellos GP, Petroni GR, Barcos M, Duggan DB, Peterson BA
- Issue date: 1995 Aug